Kidney Failure, Chronic Clinical Trial
Official title:
Correlations Between BNP and Dry Weight, and Between Troponin and Mortality, in Hemodialysis Patients
Beta Natriuretic Peptide (BNP) is regarded as the most sensitive test for congestive heart
failure (CHF). BNP has also been found to be highly predictive of other conditions including
pulmonary hypertension, pulmonary embolism and in the general population where mild
increases are associated with stroke and heart attack. BNP is also weakly and variably
correlated with renal function.
We believe that each dialysis patient will have an ideal or "dry" BNP level which will
accurately and reproducibly reflect their optimal fluid status. Secondary hypotheses are
that baseline BNP and troponin, as well as changes in BNP and troponin during dialysis, will
be highly predictive of mortality and adequacy of dialysis.
Plasma BNP is regarded as the most sensitive test for congestive heart failure (CHF).
Multiple studies have shown that BNP is a distress hormone released by the distended left
ventricular myocardium which correlates significantly with left ventricular wedge pressure
and all-cause mortality in those with CHF and acute coronary syndromes. BNP has also been
found to be highly prognostic across a wide variety of other conditions including pulmonary
hypertension, pulmonary embolism and in the general population where mild increases are
associated with stroke and heart attack. BNP is weakly and variably correlated with renal
function. How much of this elevation is related to renal clearance or the perturbations of
the circulation that uremia, hypertension and chronic fluid overload cause is speculative.
There is a paucity of information about BNP levels in hemodialysis (HD) patients.
Intuitively, BNP levels should be an ideal marker for left ventricular preload or dry weight
in the HD population. Furthermore since BNP has a short half-life of 20 minutes, serial
measurements during dialysis would be expected to rapidly reflect ultrafiltration and fluid
status. Currently the amount of fluid removed during dialysis is defined clinically by
inter-dialysis weight gain, hypertension, edema or dyspnea. Accurate assessment of ideal or
dry weight is critically important in HD patients as both fluid overload and intravascular
dehydration can have fatal consequences in this very frail population.
The few published articles on BNP as a marker for adequacy of dialysis have given
conflicting data and have been flawed by both small sample size and not doing sequential
measurements on each patient.
Cardiac troponins are well-established markers of myocardial injury. Both troponin I and T
subtypes are regulatory proteins that help coordinate the actions of actin and myosin.
Existing both in the cytosol and in the structure of the myocardium, their release is
believed to correlate with the breakdown of actin and myosin in the area of myocardial
damage. Elevated troponin levels have also been correlated with pulmonary embolism and other
sources of right heart strain. Their use in the setting of patients with ESRD has been less
clear. Sampling of asymptomatic ESRD patients found a significant percentage of them to have
elevated troponins. Proposed mechanisms for this increase include impaired renal excretion,
left ventricular hypertrophy, endothelial dysfunction, stretch mediated troponin release,
and leakage of cytoplasmic free troponin secondary to poor membrane integrity. Regardless of
the mechanism, a large study of asymptomatic patients found significantly increased
mortality in those with increased troponins.
While the correlation between increased troponins and mortality has been shown, the effects
of hemodialysis on troponin levels has yet to be demonstrated in published studies.
HYPOTHESIS: We believe that each dialysis patient will have an ideal or "dry" BNP level
which will accurately and reproducibly reflect their optimal fluid status. Subsidiary
hypotheses are that baseline BNP and troponin, as well as changes in BNP and troponin during
dialysis, will be highly predictive of mortality and adequacy of dialysis.
;
Observational Model: Case-Only, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03246984 -
VALUE- Vascular Access Laminate eUropean Experience. A Post Market Surveillance Study to Assess the Safety and Effectiveness of VasQ
|
N/A | |
Completed |
NCT02922361 -
Spending and Outcomes for Complex Medicare Advantage Patients
|
||
Completed |
NCT02235571 -
iChoose Decision Kidney Aid for End-Stage Renal Disease Patients
|
N/A | |
Completed |
NCT01922843 -
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
|
Phase 2 | |
Completed |
NCT01933789 -
Improving Communication About Serious Illness
|
N/A | |
Completed |
NCT01930396 -
Use of Tinzaparin for Anticoagulation in Hemodialysis
|
Phase 4 | |
Not yet recruiting |
NCT01674660 -
Factors Associated With Interdialytic Blood Pressure Variability in Maintenance Hemodialysis Patients
|
N/A | |
Not yet recruiting |
NCT01157260 -
The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease
|
Phase 4 | |
Completed |
NCT01209403 -
Insulin-like Growth Factor (IGF-I) in Hemodialysis Patients
|
Phase 4 | |
Completed |
NCT00753116 -
Renal Denervation in End Stage Renal Disease Patients With Refractory Hypertension
|
Phase 1 | |
Recruiting |
NCT00532688 -
N-Acetylcysteine in Heart Failure With Coexistent Chronic Renal Failure
|
Phase 2/Phase 3 | |
Completed |
NCT00534144 -
Comparison Between Effects of Two Iron Preparations on Protein in the Urine
|
Phase 1 | |
Completed |
NCT00528788 -
How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis
|
Phase 4 | |
Completed |
NCT00226902 -
Vascular Reactivity in Kidney Disease Patients
|
N/A | |
Completed |
NCT00382044 -
Audit of the Effect of Changing From IV to SC Administration of ESA's in Haemodialysis Patients
|
N/A | |
Recruiting |
NCT00235287 -
Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease
|
Phase 4 | |
Completed |
NCT00224081 -
DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin)
|
Phase 4 | |
Completed |
NCT00071214 -
Study to Evaluate the Effectiveness of StaphVAX in Adults on Hemodialysis
|
Phase 3 | |
Completed |
NCT00049907 -
Cardiac and Renal Disease Study (CARDS)
|
N/A | |
Completed |
NCT00006297 -
Risk Factors for CV Disease in a Dialysis Cohort
|
N/A |